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Abstract
Objectives: Hepatocellular Carcinoma is the commonest form of cancer in The Gambia, and
although Hepatitis B and Hepatitis C are known risk factors, accurate baseline data on Hepatitis B
and Hepatitis C distribution in the region are limited. Similarly data including information on the
involvement of the viruses in HCC remains unknown. The current study was undertaken to
estimate the risk of HCC in relation to HCV and HBV in The Gambia.
Methods: Thirteen patients with histological proven history of HCC and 39 healthy controls were
enrolled in the study. Each subject blood was screened individually for anti-HCV using ORTHO
HCV 3.0 ELISA test system (Ortho-Clinical Diagnostics, Inc, U.S.A) and for HBsAg using
QUADRATECH CHECK 4-HBs one step generation hepatitis B surface antigen test kit
(VEDALAB, France) following the manufacturers instructions.
Results: HBsAg and anti-HCV was detected in 38.5 %(5/13) and 7.7% (1/39) of the persons with
a history of HCC respectively. HBsAg but not anti-HCV was detected in 12.8% (5/39 of the case
control subjects. HBsAg and HCV rates among the HCC patients were higher in men than women.
Rates were highest in patients 48 years and above (37.5%; 3/8). No patient was found with anti-
HCV and anti-HBV.
Conclusion: These results indicate that the involvement of HBV and HCV in HCC in the country
is in a ratio of 5:1 and that these two viruses might be independently involved in the pathogenesis
of the disease. The study revealed a statistically significant association (p = 0.04) between HBsAg
and HCC patients.
The results also indicate that up to 50% of HCC cases in the country may be due to non viral factors 
and calls for further studies in this regard. These findings call for provision of diagnostic facilities 
for these viruses in hospitals and for their routine screening in blood banks while intervention 
programmes should be put in place.
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Hepatocellular carcinoma (HCC) is a common cancer
worldwide, which occurs substantially as a complication
of liver cirrhosis [1]. Chronic infection with Hepatitis B
virus (HBV) and Hepatitis C virus (HCV) has been associ-
ated with the disease [2,3] with higher incidences reported
in countries where Hepatitis B and or Hepatitis C are
endemic [4,5] HCV has a lower global prevalence than
HBV and is more often associated with HCC in economi-
cally developed regions [6,7]. Globally, HCC is increas-
ingly becoming a major health concern with estimates of
500,000 new cases reported annually [8]. Some studies
have shown a direct correlation between the geographical
distribution of HBV and HCV and HCC prevalence [7]. In
Japan and Italy where higher HCV prevalence is very high,
HCC has been shown to be more prevalent [8]. In the
United States of America, it is estimated that the disease
burden from HCV is likely to rise considerably over the
next 10–20 years increasing demands on liver transplan-
tation [9]. In West Africa, some studies have shown that
both HBV and HCV infections are common but the role of
HCV in acute infection is still not clear [10-13].
In the Gambia hepatocellular carcinoma (HCC) has been
defined as the country's commonest form of cancer [14],
and Hepatitis B virus (HBV) infection is endemic [15,16].
However, like other developing countries in the West Afri-
can region, accurate data including information about
incidence and prevalence of both HBV and HCV or the
involvement of the viruses in HCC is lacking or limited
[13]. The problem is further compounded by the non-
existence of facilities for HCV or HBV diagnosis in estab-
lished hospitals in the country making it difficult to have
a baseline data on HBV or HCV distribution in the coun-
try. The few available studies however, have shown Hepa-
titis B prevalence in the Gambia to be quite high [15,16].
The Gambia National blood transfusion services (GAM-
BLOOD), which were recently put in place, are yet to com-
mence screening of blood for HCV or HBV. The present
study was carried out to compare the involvement of HBV
and HCV in HCC in the country.
Subjects, Materials and Methods
This study is part of an on-going study on HIV and HCV
coinfection and was approved by the Department of State
for Health. The study population consisted of a total of 13
HCC patients seen consecutively at the Royal Victoria
Teaching Hospital (RVTH), Banjul between the months of
July to December 2002. The patients were aged 32 years to
76 years and were made up of 11 men and 2 women.
Patients were enrolled for the study following informed
consent. Each patient was matched by three persons on
the basis of age and sex. The primary choice of control
group persons were blood donors, however due to the
lack of female blood donors, the two female HCC patients
were matched with two women attending antenatal clinic
in their first trimester of pregnancy, and four other female
patients with history of malaria. In all a total of thirty-nine
healthy controls made up of 33 blood donors and 6
women were enrolled for the study. Both the HCC
patients and control subjects were unaware of their HCV
or HBV status prior to the commencement of the study.
Blood samples were collected from each participant and
linked by name and code number. Samples were sepa-
rated within 8 hours of collection, screened individually
for anti-HCV using ORTHO HCV 3.0 ELISA test system
(Ortho-Clinical Diagnostics, Inc, U.S.A) a third genera-
tion enzyme linked immunosorbent assay (ELISA). Per-
sons reactive to ORTHO HCV 3.0 ELISA test were
considered anti-HCV positive [17]. Hepatitis B surface
antigen (HBsAg) test was carried using QUADRATECH
CHECK 4-HBs one-step generation hepatitis B surface
antigen test kit (VEDALAB, France) following the manu-
facturers instructions.
HBsAg and anti-HCV prevalence rates were calculated to
reflect the relative frequency of each disease while Odds
ratio (OR) and ninety five percent confidence interval
(95% CI) was calculated using the Fisher Exact Test to esti-
mate the strength of the association between each infec-
tion and possible risk factor[18].
Results
The mean age of the HCC patients was 46 years and 43
years for the men and women respectively. The mean age
of the control subjects was 45.7 years for the men and 43
years for the women. The mean age of the HCC patients
with HbsAg was 47.8 years, while the only patient with
anti-HCV was aged 54 years.
Hepatitis B surface antigen (HbsAg) was present in 38.5
%(5/13) of the HCC patients (p = 0.04; 95% CI: 1.03–
8.73) and in 12.8% (5/39) of the control subjects (p =
0.046; 95% CI: 0.11–0.97). Anti-HCV antibodies were
detected in 7.7 % (1/13) of the HCC patients. No anti-
HCV antibody was detected among any of the control sub-
jects. Similarly no HBsAg or nor anti-HCV was detected in
more than half (53%; 7/13) of the HCC patients.
The male HCC patients had an anti-HCV prevalence of 9.1
%(1/11) and a hepatitis B surface antigen (HBsAg) preva-
lence of 36.4 %(5/11). The two female HCC patients who
participated in this study were both anti-HCV and HBsAg
negative. No patient was found with anti-HCV and anti-
HBV.
The hepatitis B surface antigen (HBsAg) prevalence for the
control group was 12.12% (4/33) for the males (95% CI:
0.097–5.43; OR 0.69). The female control subjects had anPage 2 of 5
(page number not for citation purposes)
International Seminars in Surgical Oncology 2005, 2:20 http://www.issoonline.com/content/2/1/20HBsAg prevalence of 16.7 % (1/6) (CI: 0.18–10.27; OR:
1.45). All the HBsAg positive control subjects were blood
donors give an HBsAg prevalence of 15.2 % (5/33). None
of the control subjects demonstrated antibody to HCV.
Hepatitis B surface antigen rates were highest in patients
48 years and above (37.5%, 3/8) (CI: 0.23–3.79; OR: 0.9).
Control subjects aged 48 years and above had a lower
HbsAg prevalence (11.1%, 2/18) than those less than 48
years (15.8 %, 3/19)}; however this was not statistically
significant (p > 0.05). There was a marginal statistically
significant association between HBsAg and HCC patients
(p = 0.04; 95%CI: 1.03–8.73, OR: 4.25).
A summary of the results of the hepatitis B surface antigen
and anti-HCV tests for the HCC patients are shown in fig-
ure 1 below.
Discussion
Hepatocellular carcinoma is generally associated with
increasing age and significantly higher HBV and HCV
prevalence have been reported among persons in their
40's and 50's respectively [4,19]. Some studies conducted
in the West African region have found a comparatively
higher HBsAg positivity in those 41 years and above.
In this study, patients had no prior knowledge of their
HCV status because HCV testing was not performed rou-
tinely, and this test was not available before this study. A
summary of the results showed that the mean age of the
HCC patients with HbsAg as 48.2 years, while the only
patient with anti-HCV was aged 54 years. This finding is
in line with similar reports [4,19]
HCC is more associated with males than females [8]. The
finding of a comparatively higher prevalence of HbsAg
and HCV among the male subjects in this study reflects
the results of other studies [8]. However, in this study the
difference was not statistically significant (p > 0.05),
although it may be due to the small number of women
participants. A similar reason may be advanced for the
finding of a comparatively higher prevalence of HBsAg
among the female case control subjects than the males
This study reveals an HBsAg prevalence of 15.2 % (5/33)
among the apparently healthy Gambian population. Even
though the sample size in the study was small, the finding
is of major public health significance. The finding also
supports a report that suggests that the virus is endemic in
the country [20]. An aggressive HBV immunization exer-
cise carried out in the country is believed to have drasti-
cally reduced the incidence of HBV [14]. An earlier work
almost a decade ago estimated an HBV prevalence of 15–
20% among the Gambian population [20]. The preva-
lence found in this study may therefore be suggestive of
stable existence of the virus in the region.
The finding of lower anti-HCV prevalence among the
HCC patients and none among the control subjects
reflects the lower prevalence of HCV and the possible low
involvement in HCC in the country. These findings are in
line with a recent report and also provide support for a
similar work conducted in Senegal a country that shares
an extensive border, language and cultural similarities
with the Gambia [14,20]. Globally 52.3% of HCC is
attributed to HBV while HCV account for about 25% [8].
The observation of higher rates of hepatitis B surface anti-
gen (HBsAg), and anti-HCV in patients with HCC than in
control subjects suggests the involvement of these viruses
in HCC [21]. Similarly, the finding of anti-HCV and
HBsAg independently among HCC patients suggests that
these two viruses might contribute independently to the
pathogenesis of HCC. This finding supports the assertion
of the independent roles of HBV and HCV in the patho-
genesis of HCC [5]. Some studies have reported the syner-
gistic role of HBV and HCV in HCC [2]. In this study no
patient was found with HBV and HCV infection simulta-
neously. This may however be due to the number of par-
ticipants enrolled in the study.
The observed involvement of HBV and HCV in HCC
patients in a ratio of 5:1 in this study is higher than that
reported previously [14]. This difference could have
resulted from the comparatively small study population.
The World Health Organization estimated an HCV
Distribution of HBsAg and anti-HCV among HCC patients according to age rangeFigu e 1
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Fig1: Distribution of HBsAg and anti- HCV among HCC patients according to age
range.
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a close epidemiological association between the HCC and
HCV was not found in Senegal [20]. Their findings suggest
that the main viral cause of HCC in the Senegal remains
HBV.
In this study the possible attributable fraction of HCC due
to HBV or HCV is 46%, thus suggestive of the involvement
of other factors. In some countries HCC has been associ-
ated with chronic exposure to toxins originating from
Aspergillus infected grains and peanuts [8]. Other associ-
ated risk factors includes cigarette smoking, prolonged
abuse of alcohol in addition to some hereditary factors
[5,8,23]. These factors were not evaluated in this study nor
are their contributory role as causative agents of HCC in
the Gambia known, however grains are the country most
staple food while cigarette smoking and groundnut con-
sumption are very common habits in the Gambia. There
is therefore need for studies to evaluate the possible
involvement of non-viral factors in HCC in the country.
Conclusion
These results suggest that HBV is endemic in the country
and is present in apparently healthy persons. It also
reveals that both HBV and HCV are actively involved in
HCC in the region, in a ratio of 5:1 and that these two
viruses might be independently involved in the pathogen-
esis of the disease. The results indicate that more than
50% of HCC cases in the country may be due to non-viral
factors and calls for further studies to address this.
The study revealed a marginally statistically association (p
= 0.04) between HBsAg and HCC patients (95%CI: 1.03–
8.73, OR: 4.25). A similar level of association was found
between HBsAg and with the case control subjects. No
such association was found for HCV. These findings make
it necessary for provision of diagnostic facilities for these
viruses in hospitals and blood banks while intervention
programmes should be put in place.
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